Giuseppe
Emeritus
Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-term Sterilizing Immunity Against Heterologous Challenge. (J Virol., abstract, edited)
4. J Virol. 2010 Feb 24. [Epub ahead of print]
Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-term Sterilizing Immunity Against Heterologous Challenge.
Schwartz JA, Buonocore L, Suguitan AL Jr, Silaghi A, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK. - Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; and National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada.
The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (Schwartz, et al. 2007 Virology 366:166-73). Here we have generated and characterized VSV-based vaccines that express the HK/156 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Post-challenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.
PMID: 20181720 [PubMed - as supplied by publisher]
-
-----
4. J Virol. 2010 Feb 24. [Epub ahead of print]
Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-term Sterilizing Immunity Against Heterologous Challenge.
Schwartz JA, Buonocore L, Suguitan AL Jr, Silaghi A, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK. - Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; and National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada.
The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (Schwartz, et al. 2007 Virology 366:166-73). Here we have generated and characterized VSV-based vaccines that express the HK/156 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Post-challenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.
PMID: 20181720 [PubMed - as supplied by publisher]
-
-----